European pharmaceutical companies urge governments to boost investment
Summary
European pharmaceutical companies are increasing their efforts to persuade cash-strapped governments in the region to enhance investments in new medicines to avoid falling behind competitors in China and the US. Recent analysis indicates that Europe is already lagging in pharmaceutical investment, clinical trials, and the development of new drugs. Moreover, European drugmakers have cautioned that insufficient healthcare spending may delay product launches and diminish investments, further widening the access gap with the US.
Analysis
European pharmaceutical companies: European pharmaceutical companies develop, manufacture, and commercialize medicines while conducting research and clinical development across the region. They are relevant to this news because industry leaders are urging financially constrained European governments to increase healthcare and innovation investment, warning that weaker support could shift future pharmaceutical investment and medicine launches toward the United States and China. China: China recently announced measures to accelerate approvals for innovative medicines and strengthen protection for pharmaceutical research, adding to competitive pressure on Europe. Policy: European drugmakers have warned that insufficient healthcare spending could lead to delayed launches and reduced investment in Europe, widening access differences with the United States. Competitiveness: Recent industry analysis says Europe is being outpaced by China and the United States in pharmaceutical investment, clinical trials, and the development of novel medicines.
Categories
macropolitics
Related sources
- https://www.bloomberg.com/news/articles/2026-09-22/pharma-bosses-warn-european-leaders-future-investment-at-risk
- https://www.reuters.com/world/us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-2026-09-18/
- https://www.efpia.eu/media/5mvbnamw/assessing-europe-s-competitiveness-as-a-location-for-the-life-sciences-industry.pdf
- https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/turning-eu-excellence-in-science-into-commercial-success-could-add-more-than-120billion-to-eu-economy-in-10-years/
- https://www.medicinesforeurope.com/wp-content/uploads/2026/06/Medicines-for-Europe-proposal-on-MFN-100626.pdf
- https://russpain.com/news/european-pharma-faces-rising-pressure-from-us-tariff-policy-shift-94187/
- http://english.scio.gov.cn/pressroom/2026-09/21/content_118706360.html
- https://www.democrata.es/en/health/the-european-pharmaceutical-company-allocates-60-billion-to-r-d-in-2025-but-yields-leadership-to-the-usa-and-china/
- https://www.upday.com/uk/46-new-drugs-from-china-just-16-from-europe-as-pharmaceutical-leadership-crumbles/kr037qz
- https://www.pharmaceutical-technology.com/features/europes-pharma-trade-with-the-us-remains-critical-despite-tariff-turmoil/
- https://www.desmoinesregister.com/press-release/story/125085/new-research-finds-chinas-share-of-first-launched-medicines-surging-as-europe-lags-and-the-u-s-lead-weakens/
- http://english.scio.gov.cn/chinavoices/2026-09/15/content_118696714.html
- https://www.independent.co.uk/news/world/americas/us-politics/china-pharma-licensing-rules-b3052509.html
- https://www.cnbc.com/2026/04/11/trump-pharma-tariffs-mfn-china-europe-biotech-stocks.html
- https://www.usnews.com/news/top-news/articles/2026-09-18/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say